COVID-19 Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

October 26 03:31 2021
COVID-19 Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
“COVID-19(CoronaVirus) – Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across COVID-19 (CoronaVirus). A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

DelveInsight’s “COVID-19 Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the COVID-19 pipeline landscapes. It comprises COVID-19 pipeline drug profiles, including clinical and non-clinical stage products. It also includes the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive COVID-19 pipeline products.     

Some of the key takeaways of the COVID-19 Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as, Amgen, Corvus Pharmaceuticals, Fulcrum Therapeutics, Synairgen Research. Revive Therapeutics, Novavax, Valneva, etc., are developing therapies for the treatment of COVID-19.

  • Emerging therapies such as Otezla (Apremilast), CPI-006, Losmapimod, SNG001 (Interferon beta-1a), Bucillamine, NVX-CoV2373, VLA2001, are expected to have a significant impact on the  COVID-19 market in the coming years.

Get an overview of pipeline landscape @ COVID-19 Clinical Trials Analysis 

COVID-19 Overview

COVID-19 is an infectious disease caused by a newly discovered coronavirus, i.e., SARS-CoV-2. It spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. CoVs are enveloped, positive-stranded RNA viruses with nucleocapsids. The pathogenic mechanism which causes pneumonia seems to be complex

COVID-19 Emerging Drugs

  • Otezla (Apremilast): Amgen

  • CPI-006: Corvus Pharmaceuticals

  • Losmapimod: Fulcrum Therapeutics

  • SNG001 (Interferon beta-1a): Synairgen Research

  • Bucillamine: Revive Therapeutics

  • NVX-CoV2373: Novavax

  • VLA2001: Valneva

For further information, refer to the detailed report @ COVID-19 Pipeline Therapeutics 

Scope of COVID-19 Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Amgen, Corvus Pharmaceuticals, Fulcrum Therapeutics, Synairgen Research. Revive Therapeutics, Novavax, Valneva, and others.

  • Pipeline Therapies: Otezla (Apremilast), CPI-006, Losmapimod, SNG001 (Interferon beta-1a), Bucillamine, NVX-CoV2373, VLA2001, and others.

Table of Contents

1

COVID-19 Report Introduction

2

COVID-19 Executive Summary

3

COVID-19 Overview

4

COVID-19- Analytical Perspective In-depth Commercial Assessment

5

COVID-19 Pipeline Therapeutics

6

COVID-19 Late Stage Products (Phase II/III)

7

COVID-19 Mid Stage Products (Phase II)

8

COVID-19 Early Stage Products (Phase I)

9

COVID-19 Preclinical Stage Products

10

COVID-19 Therapeutic Assessment

11

COVID-19 Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

COVID-19 Key Companies

14

COVID-19 Key Products

15

COVID-19 Unmet Needs

16 

COVID-19 Market Drivers and Barriers

17

COVID-19 Future Perspectives and Conclusion

18

COVID-19 Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ COVID-19 Drugs Pipeline Report

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/